Want to see ZTS full AI Analyst Report?
ZTS Stock Chart & Stats
$77.29
$1.57(2.08%)
At close: 4:00 PM EDT
$77.29
$1.57(2.08%)
Day’s Range― - ―
52-Week Range$68.77 - $147.93
Previous Close$76.98
Volume3.47M
Average Volume (3M)4.44M
Market Cap
$33.07B
Enterprise Value$37.58B
Total Cash (Recent Filing)$1.68B
Total Debt (Recent Filing)$9.24B
Price to Earnings (P/E)13.1
Beta0.36
Next Earnings
Nov 05, 2026EPS Estimate
1.51Next Dividend Ex-DateN/A
Dividend Yield2.62%
Share Statistics
EPS (TTM)6.08
Shares Outstanding413,223,600
10 Day Avg. Volume4,215,708
30 Day Avg. Volume4,444,028
Financial Highlights & Ratios
PEG Ratio2.04
Price to Book (P/B)16.75
Price to Sales (P/S)5.89
P/FCF Ratio24.44
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue3.95
Enterprise Value/Gross Profit5.57
Enterprise Value/Ebitda9.41
Forecast
1Y Price Target
$88.00Price Target Upside13.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)6.21
Revenue Forecast (FY)$9.27B
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Cash GenerationHigh margins and substantial cash generation indicate a resilient, asset-light earnings model with strong conversion from profit to cash. This provides Zoetis with funding for research, product launches, acquisitions, dividends, and share repurchases while supporting durability through market cycles.
Diversified Growth Across Livestock, Diagnostics And International MarketsGrowth is supported by multiple businesses and geographies rather than one narrow franchise. Livestock, diagnostics, international markets, and emerging-market demand can offset weakness in U.S. companion animals, improving portfolio resilience and sustaining future expansion.
Product Innovation And Regulatory ExpansionThe Convenia RTU approval expands Zoetis’s treatment offering with a differentiated dosing format that may improve compliance and simplify care for owners and veterinarians. Regulatory approvals also extend the commercial life and strategic reach of the company’s portfolio.
Bears Say
Lowered 2026 OutlookThe reduced outlook signals that current operating pressure is material enough to affect full-year earnings, not merely quarterly results. Declining revenue and profit guidance can constrain near-term reinvestment capacity and indicate that recovery in core franchises may take time.
Companion Animal Weakness And Competitive PressureWeakness in the large companion-animal franchise creates a meaningful drag on the company’s growth profile. New entrants, discounting, rebates, and lower clinic visits may pressure market share and make revenue and margin recovery dependent on improved demand and execution.
Leverage Volatility And Reduced Equity CushionHistorically elevated leverage and declining equity reduce the balance-sheet cushion available to absorb operational setbacks. The sharp difference between annual and TTM debt figures also makes leverage trends harder to interpret, limiting confidence in financial flexibility.
Zoetis News
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $68.77 and its highest was $147.93 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $33.07B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Aug 06, 2026. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.852 by $0.018.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.53 which represents an annual dividend yield of 2.62%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.51.
How many shares outstanding does Zoetis have?
Zoetis has 413,223,600 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.87 in its last earnings report, beating expectations of $1.852. Following the earnings report the stock price went up 3.871%.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in ZTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zoetis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$88.00 (13.86% Upside)
$88.00 (13.86% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 74%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.45%
12-Months-Change
Fundamentals
Return on Equity
69.25%
Trailing 12-Months
Asset Growth
4.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zoetis
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
ZTS Company Deck
ZTS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mixed picture: clear strengths in Livestock, Diagnostics, international and continued pipeline progress, plus disciplined cost and capital return actions. However, material weakness in core Companion Animal markets—especially U.S. Dermatology and parasiticides—intensified competitive promotional activity, declining clinic visits, price realization pressure from gross-to-net investments, generics, and a meaningful downward revision to full-year guidance. While the portfolio diversification and cost actions provide resilience, the near-term trends in the company’s largest franchise create significant headwinds.View all ZTS earnings summariesZTS Revenue Breakdown
20.69% Vaccines
24.73% Parasiticides
18.53% Dermatology
10.94% Anti-infectives
8.87% Pain and sedation
7.36% Other pharmaceuticals
4.58% Animal health diagnostics
2.78% Other non-pharmaceuticals
0.29% Medicated feed additives
1.23% Contract manufacturing & human health
ZTS Stock 12 Month Forecast
Average Price Target
$88.00
▲(13.86% Upside)
Technical Analysis
Ownership Overview
0.08% Insiders
22.76% Mutual Funds
2.98% Other Institutional Investors
42.75% Public Companies and Individual Investors